Clinical trials: Prostate Cancer Patients Treated by Radiotherapy
Prostate Cancer
Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
RATIONALE: Specialized radiation therapy that delivers a high-dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00528866
- Testing
- bicalutamide, docetaxel, flutamide
- Where
- 70 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer
This phase II trial studies how well finite androgen ablation with or without abiraterone acetate and prednisone work in treating patients with prostate cancer that has come back.
- Trial name
- NCT01786265
- Testing
- Abiraterone Acetate, Bicalutamide, Degarelix
- Where
- United States
- Volunteers
- 310 people
- Sponsor
- M.D. Anderson Cancer Center
Astrocytoma, Brain Cancer
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
This is a multi-center, open-label, dose escalation study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of QBS10072S in patients with advanced or metastatic cancers…
- Conditions
- Astrocytoma, Brain Cancer, Brain Metastases, Bladder Cancer
- Trial name
- NCT04430842
- Testing
- QBS10072S
- Where
- 2 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Quadriga Biosciences, Inc.
Prostate Cancer
CT Scans in Guiding the Treatment of Patients With Prostate Cancer Who Are Undergoing Radiation Therapy
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Multiple CT scans may improve the accuracy of radiation therapy for prostate cancer.
- Trial name
- NCT00020891
- Testing
- computed tomography, radiation therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
This phase II trial compares the effect of FDG-positron emission tomography (PET)-guided metastasis directed radiation therapy (MDRT) in combination with standard treatments to standard treatments alone in treating patients with…
- Conditions
- Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06244004
- Testing
- Antiandrogen Therapy, Bone Scan, Computed Tomography
- Where
- 6 sites in United States
- Volunteers
- 125 people
- Sponsor
- Northwestern University
Prostate Cancer
Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00348998
- Testing
- bevacizumab, bicalutamide, goserelin acetate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Virginia Mason Hospital/Medical Center
Prostate Cancer
Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer
RATIONALE: Selenomethionine may slow the growth of prostate cancer. Giving selenomethionine before surgery or internal radiation therapy may be an effective treatment for prostate cancer.
- Trial name
- NCT00736164
- Testing
- selenomethionine
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
The primary objective of the study was to compare the efficacy of brachytherapy versus brachytherapy + triptorelin 22.5 mg (single injection) in subjects with recurrence of prostate cancer previously treated with radiotherapy.
- Trial name
- ANABRAQ (NCT01374087)
- Testing
- Triptorelin 22.5 mg, Brachytherapy
- Where
- 11 sites in Spain
- Volunteers
- 32 people
- Sponsor
- Ipsen
Prostate Cancer
New Treatment Modalities for Localized Prostate Cancer
The purpose of this study is to evaluate the effectiveness of four of the nowadays most established primary treatments for patients with clinically localized prostate cancer (active surveillance, robot-assisted radical…
- Trial name
- TTOPROST/OBS (NCT05523856)
- Testing
- Active Surveillance, Robot-Assisted Radical Prostatectomy, Intensity-Modulated Radiotherapy
- Volunteers
- 480 people
- Sponsor
- Fundacion IMIM
Cancer
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells.
- Trial name
- NCT00003704
- Testing
- capecitabine, radiation therapy
- Where
- 18 sites in United States, Canada
- Volunteers
- 51 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer Patients Treated by Radiotherapy
Post-marketing Surveillance Regarding Efficacy and Safety of SpaceOAR™
A treatment with SpaceOAR™ hydrogel does reduce late toxicity Grad 2 and Grad 3 of radiation therapy in prostate cancer patients
- Trial name
- NCT01999660
- Testing
- SpaceOAR™ implantation
- Where
- Germany
- Volunteers
- 119 people
- Sponsor
- CS Diagnostics GmbH
Prostate Cancer
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Selenomethionine may slow the growth of prostate cancer. Testosterone can cause the growth of prostate cancer cells. Finasteride may fight prostate cancer by lowering the amount of testosterone the body makes.
- Trial name
- NCT00736645
- Testing
- selenomethionine, finasteride
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer Patients Treated by Radiotherapy
Two-fraction Proton Therapy With MRI Guidance for Prostate Cancer: A Phase II Trial
This study is testing a shorter treatment method for prostate cancer using proton therapy (PT), which is very precise and may cause fewer side effects compared to traditional radiation.
- Trial name
- PT2 (NCT07130682)
- Testing
- Pencil Beam Proton Therapy Treatment Machine
- Where
- Hong Kong
- Volunteers
- 35 people
- Sponsor
- Hong Kong Sanatorium & Hospital
SBRT, Radical Prostatectomy
Post-Prostatectomy Linac-Based Ultrahypofractionated Radiotherapy for Patients With Localized Prostate Cancer
Radical prostatectomy is a common treatment for localized prostate cancer. More than 30% of men who undergo surgery will subsequently develop recurrence, particularly in patients with adverse features where the risk may be even…
- Trial name
- PLUTO (NCT04067570)
- Testing
- SBRT
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as triptorelin, may lessen the amount of androgens made by the body. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00667069
- Testing
- triptorelin, adjuvant therapy, 3-dimensional conformal radiation therapy
- Where
- 17 sites in France
- Volunteers
- 424 people
- Sponsor
- UNICANCER
Metastatic Cancer, Prostate Cancer
Strontium Compared With Radiation Therapy in Treating Patients With Hormone-Refractory Prostate Cancer With Painful Bone Metastases
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for prostate cancer.
- Trial name
- NCT00002503
- Testing
- strontium chloride Sr 89
- Where
- 21 sites in Belgium, Denmark and 7 more
- Volunteers
- 204 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
HRQOL in Prostate Cancer Patients Treated With Radiotherapy
The study primarily aims at evaluating health-related quality of life after radiotherapy for prostate cancer, using modern hypofractionated radiotherapy schedules. Study design is a prospective observational cohort study.
- Trial name
- PRORAD (NCT05645237)
- Testing
- radiotherapy
- Where
- Netherlands
- Volunteers
- 600 people
- Sponsor
- Erasmus Medical Center
Prostate Cancer
Radiation Therapy in Treating Patients Receiving Hormone Therapy for Prostate Cancer (GETUG-AFU 18)
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00967863
- Testing
- 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy
- Where
- 25 sites in France
- Volunteers
- 500 people
- Sponsor
- UNICANCER
Prostate Cancer
Radiation Therapy With or Without Goserelin in Treating Patients Who Have Undergone Surgery for Recurrent or Refractory Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as goserelin, may stop the adrenal glands from making androgens.
- Trial name
- NCT00423475
- Testing
- goserelin acetate, adjuvant therapy, radiation therapy
- Where
- 31 sites in France
- Volunteers
- 743 people
- Sponsor
- UNICANCER
Prostate Cancer
Evaluate Recovery of Testosterone for Patients Using Eligard
The purpose of this study is to determine if testosterone will recover to 90% by year 1 after using Eligard.
- Trial name
- Eligard (NCT01136226)
- Testing
- Eligard (TM)
- Volunteers
- 42 people
- Sponsor
- Chesapeake Urology Research Associates